In specific tumour types or molecular subgroups, the prevalence for CT reaches 100%, such as in medulloblastoma with germline TP53 mutations (Li-Fraumeni syndrome, LFS), which is the focus of this study. This evidence concerns the gene TP53 and neoplasm.